Publicidad
Artículo original 13 de octubre de 2024

Modelo de atención para administrar terapia con péptidos radiomarcados con Lutecio-177 en pacientes con tumores neuroendocrinos metastásicos: experiencia de un centro de referencia

Referenciar Imprimir Descargar PDF

Referencias

  1. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124–30.
  2. Mujica-Mota R, Varley-Campbell J, Tikhonova I, et al. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or  metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Health Technol Assess 2018;22:1–326.
  3. Pinto MP, Muñoz Medel M, Carrillo D, et al. Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective. Horm Cancer 2019;10:3–10.
  4. GPStrategy. Sistema de Información para Análisis Institucional. SIAI. 2018.
  5. Valkema R JM  Breeman WA, Kooij P, et al BW. Phase I Study of Peptide Receptor Radionuclide Therapy with [111In-DTPA0] Octreótide: The Rotterdam Experience. Semin Nucl Med. 2002;32:110–22.
  6. Prasad V, Baum R. Changing Role of somatostatin receptor targeted drugs in NET: Nuclear Medicine`s view. J Pharm Pharmaceut Sci 2007;10:321s–337s.
  7. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017;376:125–35.
  8. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417–22.
  9. Kaltsas GA PD,  Grossman AB MP. Treatment of advanced neuroendocrine tumours with radiolabeled somatostain analogues. Endocr Relat Cancer 2005;12:683–99.
  10. Kwekkeboom DMJ, Paganelli G, Stanislas L, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):62S-6S.
  11. Pavel M, O’Toole D, Costa F, et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016;103:172–85.
  12. Shah MH, Goldner WS, Halfdanarson TR, et al. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw 2018;16:693–702.
  13. Delgado N, Martinez M, Reyes A de los, Llamas A. Preliminary results of the evaluation of 99mTc-EDDA/HYNIC-Tyr3- octeotride prepared from lyophilized kits vs 111 In-DTPA-octeotride with SPECT images in patients with metastatic neuroendocrine tumors in the National Cancer Institute of Bogota-Colombia. International Conference on Clinical PETand Molecular Nuclear Medicine. IAEA; 2007:204-5.
  14. Delgado N, Rada J, Villamil C, et al. Elaboración de un kit de [177Lu-DOTA-Tyr3] Octreotate calidad farmacéutica para ser administrado en terapia de tumores neuroendocrinos metastásicos en pacientes del Instituto Nacional de Cancerología. XI Congreso Colombiano de Medicina Nuclear. 2013.
  15. De los Reyes A, Llamas-Olier A, Martí A, et al. Eficacia de lutecio-177 DOTATATE/TOC en pacientes con tumores neuroendocrinos bien diferenciados en estado avanzado. Ensayo clínico fase II. Rev Colomb Cancerol 2021;25:13-24.
  16. Krenning E, Valkema R, Kooij P, Al. E. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Ital J Gastroenterol Hepatol 1999;31(suppl 2):S219–S223.
  17. Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology 2017;105:295–309.
  18. Kendi AT, Halfdanarson TR, Packard A, et al. Therapy With 177 Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors. AJR Am J Roentgenol 2019;213:309–17.
  19. Carlsen EA, Fazio N, Granberg D, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: A multicenter cohort study. Endocr Relat Cancer 2019;26:227–39.
  20. Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013;40:800–16.
  21. Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.
  22. Del Olmo-García MI, Prado-Wohlwend S, Bello P, et al. Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions. Cancers (Basel) 2022;14:584-604.
  23. Servicio Geológico Colombiano. Servicio Geológico Colombiano. Trámites y Servicios [Internet]. Available from: https://www2.sgc.gov.co/tramites-nucleares/Paginas/default.aspx
  24. Ministerio de Salud y Protección Social. Farmacovigilancia [Internet]. Farmacovigilancia 2019 [cited 2022 Jul 13]. Available from: http://medicamentosaunclic.gov.co/contenidos/Farmacovigilancia.aspx
  25. Ministerio de Salud y Protección Social. Resolución número 4245 de 2015, por la cual se establecen los requisitos para obtener la certificación en Buenas Prácticas de Elaboración de Radiofármacos y se adopta el instrumento para su verificación. 2015.
  26. Garske U, Sandström M, Johansson S, et al. Minor changes in effective half-life during fractionated 177Lu-octreotate therapy. Acta Oncologica 2012;51:86–96.
  27. Pardo A, Del Olmo García D, Isabel M, et al. Consenso de manejo de la terapia con péptidos marcados con radionúclidos (PRRT) en el tratamiento de tumores neuroendocrinos (TNEs). Grupo Español de Tumores Neuroednocrinos. 2017.
  28. O´Connor J, Acosta Haab G, Armas I, et al. Recomendaciones para el diagnóstico y el tratamiento de TNE GEP. Reunión intersociedades, Academia Nacional de medicina. Acta Gastroenterol Latinoam 2020;50(supl 1):1-33.
  29. Fierro-Maya L, Prieto C, Garavito G, et al. Resultados del tratamiento multidisciplinario de tumores neuroendocrinos de intestino delgado. Rev Colomb Cancerol 2018;22:105–11.
  30. Aura D, Erazo A, Solís V. Actualización de las Guías de Diagnóstico y Tratamiento de Tumores Neuroendocrinos y Gastroenteropancreáticos del Grupo de Trabajo en NET-GEP de México 2011;. pp. 37.
  31. Balter H, Trindade T, Terán M, et al. 177Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay. Curr Radiopharm 2016;9:85–93.
  32. Gomes G do V. Diretriz para terapia com OCTREOTATO-DOTA-177Lu. Guidelines SBMN 2016.
  33. Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res 2017;23:4617–24.
  34. Marin-Oyaga V, Gutierrez-Villamil C, Mejia-Lorpez A, et al. Terapia con [177Lu-Dota0-Tyr 3]-Octreotate (177Lu-Dotatate) en pacientes con tumores avanzados de origen neuroendocrino: experiencia inicial y resultados preliminares. Rev Cienc Salud 2017;15:335–44.
  35. Costa AFE, Jones BD, Costa IA, et al. Tratamento de tumores neuroendócrinos por medicina nuclear: revisão sistemática da eficácia e segurança do radiofármaco Dotatate-177Lu. Rev Interdisciplin Estud Exp Anim Hum 2014;6:15-21.
  36. Pignata SA, Ferrantelli A, Baldari S. Peptide receptor radionuclide therapy plus somatostatin analogues for a neuroendocrine tumour combined and maintenance treatment. Clin Transl Imaging 2019;7:373–6.
  37. Sowa-Staszczak A, Stefanska A, Chrapczynski P, et al. Does combination of “cold” and “hot” somatostatin analogs prolong survival of  patients with neuroendocrine neoplasms? Endocr J 2017;64:171–7.
  38. Evangelista L, Cecchin D, Kunikowska J. Challenges in theragnostics. Q J Nucl Med Mol Imaging 2021;65:371–5.